Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020-Off-patent Chemo-regimens to Retain Dominance Despite New Launches

1
Ovarian Cancer Therapeutics in Asia-Pacific
Markets 2020
2
Summary

• GBI Research, a leading business intelligence
  provider, has released its latest research
  report Ovarian Cancer Therapeutics in
  Asia-Pacific Markets to 2020 - Off-patent
  Chemo-regimens to Retain Dominance Despite New
  Launches.
• The report provides estimates of the market size
  for 2013, along with forecasts until 2020 for the
  Asia-Pacific markets of India, China, Australia
  and Japan. It also covers disease epidemiology,
  treatment algorithms, treatment patterns,
  in-depth analysis of clinical trials including
  failure rates and pipeline analysis, and analysis
  of deals relevant to Ovarian Cancer (OC).
• Read The Complete Report On http//www.bigmarket
  research.com/ovarian-cancer-therapeutics-in-asia-p
  acific-to-2020-off-patent-chemo-regimens-to-retain
  -dominance-despite-new-launches-market

3
Report Description

• Platinum-based chemotherapy, predominantly the
  chemotherapy regimen paclitaxel and carboplatin,
  is the standard of care for the treatment of
  platinum-sensitive OC (both first-line and
  recurrent).
• The initial treatment is quite effective, with
  the majority of patients entering remission.
  However, almost all relapse, and after successive
  periods of remission and relapse either die or
  progress to platinum-resistant disease, for which
  the prognosis is poor. There is a clear gap in
  the market for maintenance therapies, as well as
  for more effective treatment options in
  platinum-resistant or refractory patients.
• To Get More Details Enquire _at_ http//www.bigmarket
  research.com/report-enquiry/176578

4
Key Segment

• Although the current developmental pipeline is
  quite crowded, efficacy with these late-stage
  drugs has been poor, at best demonstrating
  minimal improvements in progression-free
  survival, but not overall survival. The promising
  investigational drug candidates olaparib and
  trebananib are expected to gain approval during
  the forecast period. However, even on approval
  they are not expected to have a high market
  penetration, owing to their minimal therapeutic
  efficacy and anticipated premium prices. As a
  result, the OC market in APAC is expected not be
  driven by new drug approvals, but primarily by
  inflation, and the increase in the prevalence of
  OC. Market revenue is forecast to rise at a
  limited CAGR of 5.1 to 417.6m in 2020.
• Despite the poor clinical performance of current
  late-stage pipeline drugs, there is evidence of
  continued interest in the OC market, with a high
  number of drug candidates in the initial
  developmental pipeline, particularly at the
  Preclinical phase. There is a wide range of novel
  molecular targets distributed among these drug
  candidates, including growth factors,
  serine/threonine protein kinases and tumor
  associated antigens. This suggests a continued
  interest in introducing more targeted therapies
  into the treatment of OC, the use of which in
  this indication lags significantly behind that in
  others in oncology.

5
Scope

• The report analyzes treatment usage patterns,
  drug types available and pipeline and market
  forecasts for OC. It covers and includes
• A brief introduction to OC, including the
  diseases pathogenesis, risk factors and
  diagnosis
• In-depth analysis of the drug combinations used
  in the treatment of OC, including analyses of
  their safety, efficacy, and place in the disease
  treatment algorithm, as well as a heat map
  comparing the drug combinations in terms of
  safety and efficacy
• A comprehensive review of the pipeline for OC
  therapies, including individual analysis of a
  number of late-stage pipeline drugs that have the
  potential to enter the market in the forecast
  period the pipeline is analyzed on the basis of
  phase distribution, molecule type and molecular
  target, and route of administration
• Additional in-depth analysis of pipeline drug
  clinical trials by phase, molecule type, trial
  size, and trial duration, and program failure
  rate analyses for each molecule type and
  mechanism of action
• Multi-scenario forecast market data to 2020,
  taking into account how it will be affected by
  the introduction of new drugs, the expiry of key
  patents on current drugs, and the changes in
  disease epidemiology across the APAC markets

6
Reasons to Buy

• The report will assist business development and
  enable marketing executives to strategize their
  product launches, by allowing them to
• Understand the efficacy and safety of the current
  monotherapies and drug combinations used in the
  treatment of OC, with in-depth analysis of the
  disease treatment algorithm
• Understand the key signaling pathways and
  molecular targets currently under investigation
  in OC drug development
• Understand the vast scope of the pipeline,
  including which molecule types and mechanisms of
  action are prominent
• Observe the trends in clinical trial duration and
  size among clinical phases and molecule types,
  and use the clinical trial failure rate analysis
  to assess the risk profiles of current and/or
  future developmental programs for OC therapeutics
• Assess the potential clinical and commercial
  impact of current late-stage pipeline molecules
  in the OC therapeutics market

7
Table Of Content

• Introduction
• Marketed products
• Pipeline Analysis
• Market Forecast 2020
• Deals and Strategic Consolidations
• Appendix
• Read The Complete TOC _at_ http//www.bigmarketresear
  ch.com/ovarian-cancer-therapeutics-in-asia-pacific
  -to-2020-off-patent-chemo-regimens-to-retain-domin
  ance-despite-new-launches-market

8
Contact Us
Deep Joshi 5933 NE Win Sivers Drive, 205,
Portland, OR 97220 United States Direct 1
[phone] Toll Free 1 [phone] Fax
1 [phone] Email help_at_bigmarketresearch
.com Web http//www.bigmarketresearch.com